Table 2.

Baseline and 1-yr BMD and Z-scores according to group

ParameterBaseline1-Year
BMD (g/cm2)Z-ScoreBMD (g/cm2)Z-Score
Kidney
    lumbar spine1.11 ± 0.020.38 ± 0.161.10 ± 0.030.34 ± 0.17
    femoral neck0.87 ± 0.02−0.04 ± 0.150.85 ± 0.02−0.17 ± 0.15
    wrist0.35 ± 0.010.18 ± 0.210.36 ± 0.01−0.03 ± 0.21a
Kidney pancreas
    lumbar spine1.04 ± 0.02a−0.33 ± 0.15b1.05 ± 0.02−0.23 ± 0.15
    femoral neck0.77 ± 0.02a−1.22 ± 0.15b0.80 ± 0.02−1.08 ± 0.15c
    wrist0.30 ± 0.01a−0.64 ± 0.24a0.30 ± 0.01−0.83 ± 0.19
Bisphosphonate
    lumbar spine1.02 ± 0.02d−0.29 ± 0.14d1.05 ± 0.02d−0.17 ± 0.14
    femoral neck0.77 ± 0.01d−1.01 ± 0.12d0.78 ± 0.01a−0.92 ± 0.13
    wrist0.32 ± 0.01−0.47 ± 0.21a0.31 ± 0.01−0.68 ± 0.20a
Calcitriol
    lumbar spine1.18 ± 0.030.77 ± 0.181.14 ± 0.030.61 ± 0.22
    femoral neck0.92 ± 0.020.35 ± 0.190.91 ± 0.020.14 ± 0.19
    wrist0.36 ± 0.010.33 ± 0.230.37 ± 0.010.15 ± 0.20
  • Kidney pancreas recipients had lower baseline BMD and Z-scores than kidney recipients. Patients who were allocated to bisphosphonates had lower BMD (spine and hip) and Z-scores (all sites) than those who were allocated to calcitriol. After bisphosphonates, 1-yr BMD improved at the lumbar spine (3.3 ± 0.9%; 95% confidence interval 1.5 to 5.1%) and femoral neck (2.0 ± 0.8%; 95% confidence interval 0.4 to 3.6%). Z-scores decreased at the wrist in kidney recipients and those who were allocated to bisphosphonates and improved at the femoral neck in kidney-pancreas recipients.

  • a P ≤ 0.05,

  • b P ≤ 0.001,

  • c P = 0.01,

  • d P ≤ 0.0001.